Responding to Covid-19 in pharmaceutical supply chains

The social and economic implications of the Covid-19 pandemic have been felt on a global scale, as millions of people were forced into lockdown, hundreds of thousands of businesses stalled their operations as healthcare systems were pushed to breaking point.

While the pharmaceutical industry has experienced increased bursts of innovation in digital solutions vaccine development and data sharing, pharma companies have also been burdened with the obligation to maintain supply chains for existing treatments and services.

In this report, Pharma Logistics IQ assesses the impact of the Covid-19 pandemic on supply chain and logistical operations through the analysis of short-term and long-term responses to disruption. We dive into significant industry trends within pharma and explore the strategic solutions in which pharma leadership can mitigate short and longstanding supply chain disruption.

Download the report to learn:

• How to manage supply chain risk and disruption when the long-term effects on operations are unknown.
• The trends affecting supply shortages on manufacturing and supply chains.
• Ways to strengthen production cycles, diversify manufacturing sites and enhance quality control measures.
• How to leverage real-world data to overcome disruptions to clinical trials during Covid-19.
• How to prepare for a digital future in supply chain management.

Download the report to also receive exclusive access to an interview with Jay Galeota, President and Chief Executive Officer for Inheris BioPharma Inc., who discusses his thoughts on how to facilitate innovation within pharma supply chains and gain a competitive advantage in an ever-changing market.